Psychedelics, like ketamine could be key to revolutionizing mental health.
In fact, according to medical university, Karolinska Institutet, “In a new study, researchers at Karolinska Institutet have further investigated the molecular mechanisms underlying ketamine’s antidepressant effects. Using experiments on both cells and mice, the researchers were able to show that ketamine reduced so-called presynaptic activity and the persistent release of the neurotransmitter glutamate.”
In addition, “Elevated glutamate release has been linked to stress, depression and other mood disorders, so lowered glutamate levels may explain some of the effects of ketamine,” says Per Svenningsson, professor at the Department of Clinical Neuroscience, Karolinska Institutet, and the study’s last author.
While further research will be needed, such news could be a major catalyst for companies such as NeonMind Biosciences (CSE:NEON)(OTC:NMDBF), Mind Medicine Inc. (NEO:MMED)(NASDAQ:MNMD), Cybin Inc. (NEO:CYBN)(OTC:CLXPF), Compass Pathways (NASDAQ:CMPS), and Tryp Therapeutics Inc. (CSE:TRYP)(OTC:TRYPF).